Evaluating Alpha Lipoic Acid as a Therapy for Geographic Atrophy

Benjamin Kim, MD
University of Pennsylvania (Philadelphia, PA)

Co-Principal Investigators

Joshua Dunaief, MD, PhD
University of Pennsylvania
Maureen Maguire, PhD
University of Pennsylvania
Year Awarded:
Grant Duration:
January 1, 2016 to June 30, 2019
Macular Degeneration
Award Amount:
Grant Reference ID:
Award Type:
Award Region:
US Northeastern
Benjamin Kim, MD

Therapeutic Evaluation of Alpha Lipoic Acid for Geographic Atrophy


The blinding lesions of the geographic atrophy (GA) form of advanced age-related macular degeneration (AMD) are responsible for 20 percent of the legal blindness in North America. Research has shown that oxidative stress and iron overload at the retina are major contributors to these atrophic lesions in AMD, consisting of localized areas of dead cells.

Currently there is no treatment available; however, there is interest in a potent antioxidant and iron chelator called alpha lipoic acid. A chelating agent is a substance whose molecules can form several bonds to a single metal ion, thus suppressing its chemical activity. Alpha lipoic acid is found in many food sources, including spinach, broccoli, and potatoes; it also is manufactured for use as a supplement.

Through a Phase II pilot clinical trial, we are testing alpha lipoic acid as a treatment for GA.

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.